Translate page

  • Presentations from the EHA2022 Congress

  • EHA 2022: Mechanisms of disease progression in chronic myeloid leukemia (S. Tiong Ong)

  • EHA 2022: Non-BCR-ABL1 biomarkers of prognosis in CML (Shady Awad)

  • COLT Meeting 2019: CML related topics

  • COLT Meeting 2019: The CML frontier

    CoronavirusApril 2022 - We are delighted to share that a first sub-analysis of the iCMLf CML and COVID-19 CANDID data has been accepted as a clinical poster presentation for the EHA 2022 Congress in June:

    COVID-19 in patients with chronic myeloid leukemia in treatment-free remission:
    Disease-severity and impact on TFR status (Saußele S et al. EHA 2022 abstract no. 1886)

    The sub-analysis of the CANDID study aimed to evaluate the outcome of SARS-CoV-2 infection in CML patients in treatment-free remission and assessed any impact on maintenance of TFR. Additional information were collected for this analysis including: molecular remission status before, during and after COVID-19 infection.

    We look forward to seeing you at EHA and sharing more details.

    Three other sub-analyses of the CANDID study are also underway:

    • How does MMR v no MMR influence outcomes for people with CML and COVID-19?
    • Does the TKI have an impact on COVID-19 severity and outcome?
    • An analysis of country income on the outcome of people with CML infected with the SARS-CoV-2 virus

    We will share more information once the analyses are complete.

    With over 1,050 cases of COVID-10 positive CML patients reported by >190 physicians from 59 countries, the iCMLf CANDID study represents the largest cohort of CML patients with COVID-19 globally. An update on the CANDID study was recently presented at the ASH Meeting 2021.

    Read the full abstract here